Dunphy, F.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 349

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

Jänne, P. A., Ou, S.-H. I., Kim, D.-W., Oxnard, G. R., Martins, R., Kris, M. G., Dunphy, F., Nishio, M., O'Connell, J., Paweletz, C., et al. (2014) · The Lancet Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 127